Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on SurModics (SRDX) and Pfizer (PFE).
SurModics (SRDX)
In a report released today, Michael Matson from Needham maintained a Buy rating on SurModics, with a price target of $68. The company’s shares opened today at $46.96.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 9.0% and a 67.2% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Cardiovascular Systems, and Zimmer Biomet Holdings.
SurModics has an analyst consensus of Strong Buy, with a price target consensus of $69, implying a 46.9% upside from current levels. In a report released today, Barrington also maintained a Buy rating on the stock with a $64 price target.
See today’s analyst top recommended stocks >>
Pfizer (PFE)
J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer today and set a price target of $46. The company’s shares opened today at $38.25, close to its 52-week low of $37.68.
According to TipRanks.com, Schott is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -7.5% and a 39.3% success rate. Schott covers the Healthcare sector, focusing on stocks such as Sienna Biopharmaceuticals Inc, Bausch Health Companies Inc, and Endo International.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $45.29 average price target, a 18.4% upside from current levels. In a report issued on July 30, Merrill Lynch also downgraded the stock to Hold with a $41 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
